Acute kidney injury (AKI) following stem-cell transplantation (SCT) contributes to a poor prognosis, yet its impact may vary depending on the timing of AKI onset. A prospective cohort study was performed to understand the significance of the onset timing in 103 allogeneic SCT (allo-SCT) recipients. AKI prior to stem-cell engraftment was defined as early AKI and subsequently occurring AKI as late AKI. Propensity score (PS) for early AKI was calculated using a logistic regression model to reduce confounding effects related to differences in clinical background between the early and late AKI groups. The cumulative incidences of early and late AKI were 22.3% and 54.9%, respectively. Non-relapse mortality (NRM) was 39.1% and 7.0%, and overall survival (OS) was 56.5% and 90.9% in early and late AKI at 100 days after AKI, respectively (Po 0.001). The cumulative incidence of chronic kidney disease (CKD) over 2 years after SCT was 41.5% and 19.1% in early and late AKI, respectively (P = 0.048). Logistic regression analysis adjusted for the PS showed that early AKI was significantly associated with OS (odds ratio (95% confidence interval); 4.63 (1.15-21.4), P = 0.031) but with neither NRM (1.25 (0.28-5.33), P = 0.766) nor CKD (1.85 (0.41-8.60), P = 0.422). In conclusion, early AKI may portend a poor survival for allo-SCT recipients.
INTRODUCTION

Allogeneic stem-cell transplantation (allo-SCT) involves a great risk of acute kidney injury (AKI).
1-3 AKI is defined as an 'abrupt decrease in kidney function', but post-SCT AKI is conventionally defined as 'a decline in kidney function within 100 days after SCT'. 2, [4] [5] [6] The 'time-window of 100 days' in the definition seems to be based on empirical evidence. According to this definition featuring a relatively long time-window, previous reports have shown that the frequency of AKI rose to as high as 69% in allo-SCT 7 and that post-SCT AKI was not only a risk factor of subsequent renal dysfunction 8, 9 but was also associated with short-and long-term survival. 7, 10, 11 However, our clinical experience allows us to speculate that these epidemiological and prognostic data on post-SCT AKI may vary depending on the timing of AKI onset.
A few previous studies showed that the prognosis of SCT recipients could be much worse in those who develop AKI prior to stem-cell engraftment than in those who develop AKI in the subsequent period. 12, 13 This is likely because SCT recipients tend to be exposed to a variety of complications, including sepsis, opportunistic infections and regimen-related toxicity, until around 2-3 weeks after SCT, during which time stem cells usually engraft. Nevertheless, there have been no specific studies to ascertain the poor prognosis of AKI that emerges prior to stem-cell engraftment.
The major objectives of this study were to examine the incidence of 'AKI prior to stem-cell engraftment' and to clarify the specific association between this early-onset AKI and shortterm mortality. In addition, we assessed the relationship between early-onset AKI and incident chronic kidney disease (CKD) following SCT.
PATIENTS AND METHODS
Study design
This study was a prospective cohort study to test the impact of 'AKI prior to stem-cell engraftment' on non-relapse mortality (NRM), overall survival (OS) and the subsequent incidence of CKD. Written informed consent was obtained from all participants before initiating conditioning therapy for SCT. The study was performed in accordance with the Declaration of Helsinki and was approved by the institutional committee on research ethics (approval number: 673-2009).
Study subjects
A total of 218 patients received allo-SCT from December 2008 to March 2012 at Tokyo Metropolitan Cancer Center, Komagome Hospital, Tokyo, Japan. The inclusion criteria at entry were as follows: (1) age 416 years; (2) recipients of allogeneic transplantation; and (3) absence of renal dysfunction at baseline, defined as an estimated glomerular filtration rate (eGFR) o60 mL/min/1.73 m 2 . Finally, 103 participants were eligible for the study.
Conditioning regimens, prophylaxis for GVHD and prophylactic antimicrobial therapy for the allo-SCT procedure Two typical conditioning regimens were included in the myeloablative procedure: one consisted of TBI (12 Gy) and cyclophosphamide (CY) (120 mg/kg), with or without cytarabine (8 g/m 2 ), and the other consisted of busulfan (BU) (16 mg/kg orally or 12.8 mg/kg IV) and CY (120 mg/kg). In addition, selective kidney shielding blocks were routinely used during TBI and this reduced the renal dose to 10 Gy. 14 In contrast, there were several non-myeloablative regimens; the most common one consisted of fludarabine (125 mg/m 2 ), melphalan (80 mg/m 2 ) and low-dose TBI (2 Gy × 2) or fludarabine (180 mg/m 2 ) plus BU (6.4 mg/kg IV). Myeloablative and non-myeloablative regimens were differentiated according to a previous report. 15 The patients were given IV infusion of donor hematopoietic cells on day 0. All patients received acute GVHD prophylaxis 1 Division of Hematology, Department of Medicine, Tokyo Metropolitan Cancer Center, Komagome Hospital, Tokyo, Japan and with continuous IV infusion of cyclosporine A (CYA) or tacrolimus (FK) and additionally short-term methotrexate (MTX). The doses were adjusted to maintain levels at 200-300 ng/mL for CYA and 10-15 ng/mL for FK. Prophylaxis of bacterial infection consisted of new oral quinolones (tosufloxacin or levofloxacin). Fluconazole or itraconazole was used as prophylaxis for fungal infection, sulfamethoxazole/trimethoprim as prophylaxis for Pneumocystis jirovecii pneumonia and acyclovir as prophylaxis for herpes virus infection.
Assessments for pretransplant conditions in SCT recipients: the disease risk and hematopoietic cell transplantation-specific comorbidity index (HCT-CI)
The disease risk was defined as follows: standard-risk diseases included acute leukemia in first or second CR; chronic myeloid leukemia in the first chronic phase; non-Hodgkin lymphoma in complete or partial chemotherapy-sensitive remission; and myelodysplastic syndrome or myeloproliferative disorder without excess blasts. All other diseases were defined as high-risk diseases. 16 In addition, HCT-CI is an integrated tool for scoring pretransplant comorbidities, including cardiac, pulmonary, hepatic and renal disorders, that are considered to affect mortality after SCT, which is commonly used in predicting mortality risks in SCT recipients. HCT-CI score o3 is defined as low risk, whereas HCT-CI score ⩾ 3 is defined as high risk of mortality. 17 Definitions of transplant-related complications For a comparison with previous reports, 7, 18 AKI following SCT was defined as a ⩾ 1.5-fold increase of serum creatinine (Cr) from baseline, occurring within the first 100 days after stem-cell infusion (day 0). Furthermore, we divided post-SCT AKI into two types according to the timing of onset: AKI prior to stem-cell engraftment as 'early AKI' and subsequently occurring AKI as 'late AKI'. The severity of AKI was evaluated according to the criteria of the Acute Kidney Injury Network (AKIN) and graded into three stages, based on serum Cr criteria of the AKIN. 19 Post-SCT CKD was defined as a decrease in eGFR o60 mL/min/1.73 m 2 that persisted for ⩾ 3 months after the time of 100 days after stem-cell infusion. Stem-cell engraftment was defined as the first of 3 consecutive days on which the neutrophil count was 4500 cells/μL. 20 eGFR was calculated based on the serum Cr concentration, using the following equation: eGFR (mL/min/1.73 m 2 ) = 194 × Cr − 1.094 × age − 0.287 × 0.739 (if female), which was developed for the Japanese population by the Japanese Society of Nephrology owing to the inaccuracy of the modified version of the modification of diet in renal disease equation for Asian people, including the Japanese. 21 Thrombotic microangiopathy was diagnosed according to the criteria of International Working Group. 22 Post-transplant infection included microbiologically documented infections and presumed infections based on clinical and/or radiological findings. 23 Febrile neutropenia was excluded if any other noninfectious etiology was highly suspected. Engraftment failure was defined as failure to achieve an ANC of 500/mm 3 by day 28 after transplantation.
Statistics
Comparisons between groups were performed using Fisher's exact test for categorical variables and Kruskal-Wallis rank-sum test for continuous variables. The cumulative incidences with a 95% confidence interval (CI) of AKI, CKD and NRM were estimated over time and the estimates for CKD and NRM were compared among the groups by Gray's test, while treating death without these events as a competing risk. Meanwhile, the probability of OS with its 95% CI was estimated by Kaplan-Meier method, in which the log-rank test was used to analyze differences among the AKI groups. The incidences of AKI and CKD were evaluated over 100 days and 2 years after the day of stem-cell infusion (SCT), respectively. A logistic regression model was derived to calculate a propensity score (PS) for developing early AKI. Variables that may affect the incidence of early AKI were included in a multivariable logistic regression model that determines the probability that 'early AKI' will develop. Given that the number of samples and outcomes were too small, the following four variables were chosen for the PS calculation: age, disease risk (high or standard), HCT-CI (⩾3 or less), and HLA compatibility (matched or mismatched), as those were significantly different between early and other groups. This model yielded a c statistic of 0.751 (95% CI, 0.611-0.808), indicating a good ability to differentiate between early and late AKI. Therefore, we used the PS as a single comprehensive variable reflecting the probability that early AKI will develop. As the scores did not have a normal distribution, they were logittransformed and used for analyses. The logit-transformed score ranged from − 13.65 to 27.88 (median, − 1.608). The association of 'early AKI' with an outcome was estimated using logistic regression analysis, unadjusted or adjusted for PS. All statistical analyses were performed with JMP version 11.2 (SAS Institute, Cary, NC, USA) and EZR, which is a graphical user interface for R, version 2.14.0 (http://www.r-project.org/). 24 A P-value o0.05 was considered significant in all analyses.
RESULTS
Characteristics of SCT patients, classified by the types of AKI The clinical characteristics of 103 SCT patients, including 57 males and 46 females, are shown in Table 1 . Median age of patients was 47 years (range: 19-69), and the median follow-up time after SCT was 771 days (range: 2-2155). The underlying hematological diseases were acute myeloid leukemia (n = 45), acute lymphoblastic leukemia (n = 27), myelodysplastic syndrome (n = 20), chronic myelogenous leukemia (n = 4), severe aplastic anemia (n = 4), non-Hodgkin lymphoma (n = 1), multiple myeloma (n = 1) and myelofibrosis (n = 1). Sources of stem cells included unrelated bone marrow (n = 74), related bone marrow (n = 7), cord blood (CB) (n = 13) and peripheral blood (n = 9). There were significant differences in age (P = 0.03), higher disease risk (P = 0.003), higher HCT-CI (P = 0.047) and mismatched HLA compatibility (P = 0.04) among the three groups.
Incidence and severity of AKI Among 103 allo-SCT recipients, early AKI occurred in 23 (22.3%) and late AKI in 44 (42.7%) within the first 100 days after stem-cell infusion. The cumulative incidence of any AKI over 100 days was 65.1% (95% CI: 55.0-73.5%), and the median time to incidence was 31 days (range: 0-100 days). The cumulative incidences of early AKI and late AKI at day 100 were 22.3% (95% CI: 14.8-30.8%) and 54.9% (95% CI: 43.2-65.1%), respectively ( Figure 1 ). The median time to early AKI was 11 days (range: 0-34 days) and that to late AKI was 43 days (15- 7%) . Although the proportion of stage 3 was more frequently observed in myeloablative than nonmyeloablative SCT, the deference between them was not statistically significant (P = 0.564).
Impact of the AKI types on prognosis after AKI Overall, 34 (33.0%) of 103 SCT patients died in the 1-year follow-up period: 16 in early AKI, 10 in late AKI, and 8 in no AKI. Ten patients (43.4%) died within 100 days after early AKI (n = 23), whereas only 4 (9.0%) died in the late AKI patients (n = 44). The causes of death in early AKI patients were non-engraftment in 6, primary disease recurrence in 2, hemorrhage in 1 and other organ failure in 1. In late AKI patients, they were primary disease recurrence in 1, hemorrhage in 1, GVHD in 1 and infection in 1. Non-engraftment was the main cause of death in early AKI patients, but the association between them did not show statistical significance (P = 0.100). Renal replacement therapy was required in three early AKI patients, but they eventually died within 100 days after SCT. Six patients were finally affected by multiorgan failure, all of whom Early-onset acute kidney injury following SCT N Shingai et al had developed early AKI. Three patients who died within 3 days after AKI were excluded from mortality analyses, as the AKI was determined to be inevitably caused by terminal conditions related to antecedent other organ failures and was not responsible for death. The NRM at 100 days after AKI was 39.1% in early AKI, whereas it was 7.0% in late AKI (P o0.001); the probability of OS after AKI was 56.5% in early AKI, whereas it was 90.9% in late AKI (P o 0.001), as shown in Figures 2a and b . Logistic regression analysis was performed to test an association of 'early AKI' with OS, NRM and CKD, unadjusted and adjusted for the PS. Early AKI was significantly associated with OS but with neither NRM nor CKD in the adjusted models, as shown in Table 2 .
Cumulative incidence of CKD after SCT Overall, 16 of 103 patients (15.5%) developed CKD in the 2-year follow-up period after SCT. As all three dialyzed patients (end-stage renal disease) died within 100 days after SCT, they were not included in the analysis. The cumulative incidence of CKD over 2 years after SCT was 18.6% (95% CI: 11.1-27.6%) and the median time to its incidence was 110.5 days (range: Abbreviations: AA = aplastic anemia; AKI = acute kidney injury; BMT = bone marrow transplantation; CBT = cord blood transplantation; Cr = creatinine; eGFR = estimated glomerular filtration rate; HCT-CI = hematopoietic stem-cell transplant-specific comorbidity index; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; NMAC = non-myeloablative conditioning; PBSCT = PBSC transplantation; SCT = stem-cell transplantation. P-value indicates the difference among three groups.
Early-onset acute kidney injury following SCT N Shingai et al 101-481 days). The cumulative incidence of CKD varied significantly among the two AKI groups (P = 0.048, Figure 3) Table 2 .
DISCUSSION
This study highlighted the clinical significance of early-onset AKI (AKI prior to stem-cell engraftment) in the setting of allo-SCT. Early AKI occurred by nearly 30 days following SCT in approximately 22% of allo-SCT recipients, and was significantly associated with lower OS, as compared with late AKI. This study may suggest that the conventional time-window (100 days) for the definition of post-SCT AKI should be shortened based on the timing of engraftment, practically to around 30 days following SCT, in the assessment of prognosis related to AKI among allo-SCT recipients. In fact, before the currently commonly used paradigm of AKI was proposed, the relevance of the timing of onset of acute renal failure had been discussed by several transplant experts. 3, 25 In the literature, they suggested that 'acute renal failure' occurring in almost the same time-window as in this study may be associated with increased mortality of SCT recipients, but solid evidence was lacking. 26 Therefore, we think that our results have provided a clear answer to this long-standing and new practical concern about post-SCT AKI.
The survival rate after developing early AKI was apparently poor, and six of the early AKI cases finally proceeded to multiorgan failure. The period prior to stem-cell engraftment may involve the worst clinical condition of SCT recipients, associated with predispositions to serious infections, regimen-related toxicity and immunological stress, resulting in sepsis, and acute inflammatory response syndrome. 27 Accordingly, the incidence of AKI during this period may become a trigger of multiorgan failure, as AKI is often accompanied by a systemic excessive inflammatory response that involves the mechanisms of developing remote extra-renal organ dysfunction. 28, 29 The occurrence of early AKI may be associated with a delay or failure of stem-cell engraftment, as the disease status of AKI might affect the function of Figure 1 . Cumulative incidence of AKI over time following the stem-cell infusion. Cumulative incidences of AKI over 100 days after stem-cell transfusion are shown, stratified by any, late and early AKI. Figure 2 . NRM and OS after AKI. Cumulative incidences of NRM and probability of OS after AKI are depicted in panels (a) and (b), respectively. Each figure is shown, stratified by early and late AKI. Asterisks (*) indicate the significant difference between early and late AKI (P o0.001). Abbreviations: AKI = acute kidney injury; CI = confidence interval; CKD = chronic kidney disease; NRM = non-relapse mortality; OR = odds ratio; OS = overall survival. Logit-transformed propensity score is used in analyses as the score has normal distribution.
Early-onset acute kidney injury following SCT N Shingai et al infused stem cells via the inflammatory condition. 26, 29 Delaying engraftment owing to several complicated factors may increase the risk of early AKI and, vice versa, early AKI may delay engraftment or induce engraftment failure. These synergistic effects of early AKI and stem-cell engraftment disorders could be involved in the very poor survival of SCT recipients.
This study did not attempt to identify risk factors for early AKI; however, it indicated that the patients categorized as being at 'high disease risk' may be predisposed to early AKI. SCT candidates with 'high disease risk' are considered to have relatively refractory underlying hematological malignancies, likely reflecting that they have undergone more repetitive chemotherapies including some nephrotoxic agents until reaching CR or PR, compared with those with standard disease risk. These adverse effects prior to SCT are likely to develop insidiously structural and/or functional kidney injury in SCT candidates, the degree of which cannot always be identified by a conventional urine test or serum Cr measurement before SCT. This study suggests that more precise and suitable investigations are warranted to detect hidden mild kidney injury at baseline, for instance, using sensitive new urinary biomarkers. 30 AKI following SCT is reported to be a risk factor for CKD. 8, 31 The Gray's analysis showed an association of early AKI with the incidence of CKD in this study. As described above, many serious complications occurred and sometimes persisted during the early phase of SCT. Therefore, mild kidney damage occurring in the early period would slowly worsen over time and thus more responsible for incident CKD, as compared with that occurring in the late period. The cumulative incidence of CKD among allo-SCT patients who developed AKI was significantly higher in early than late AKI. Meanwhile, the proportion of severe AKI with AIKIN stage ⩾ 2 was quite high among patients who developed early AKI; however, one should be careful with this analysis. In order for a patient to develop CKD, the patient must have lived long enough to develop CKD. As severity of AKI is associated with high mortality, those with severe AKI may not develop CKD because of the higher mortality. In addition, the significant impact of early AKI on CKD disappeared in the logistic analysis, adjusted for the PS. Further in-depth study will be necessary to make a clear answer to the effect of the timing and severity of AKI following allo-SCT.
This study has some limitations. First, the major issue was weak statistical power owing to the too small number of outcomes for analyzing many covariates. Given that the number of samples and outcomes were too small for multivariate analysis, the number of covariates chosen was inevitably limited when we calculated the PS for each patient. Although the conventional 'PS matching' analysis might have been preferable, it was unfeasible in this study as the number of matching pairs between early and late AKI was too few for appropriate analyses. Instead, we constructed a bivariate logistic regression model for each outcome, adjusted for the PS. Second, we could not fully clarify whether the effect of onset timing of AKI on death or on CKD was independent from the severity of AKI, owing to the weak statistical power. However, 10 (50%) died in 20 early AKI with AKIN stage ⩾ 2, whereas only 2 (8.7%) died in 23 late AKI with AKIN stage ⩾ 2 patients. These data simply may suggest that early AKI with high AKIN stage would be most fatal in allo-SCT recipients. Third, the lack of a pathological perspective was another type of limitation. With regard to renal biopsy, it could be crucial to probe the cause (s) of CKD as well as AKI following SCT; however, it is generally unfeasible in the early period of SCT owing to the perceived risks. Incidentally, a previous autopsy report of SCT recipients 26 showed that no clear explanation was obtained by kidney autopsy in the majority of patients who developed severe AKI following SCT. The authors speculated, therefore, that renal function impairment was mainly caused by hemodynamic rather than structural disorder. Similarly, our autopsy case indicated that specific causes or risks of AKI following SCT might not be clarified even if a kidney autopsy study is performed. 32 In conclusion, early AKI emerges approximately in one-quarter of allo-SCT recipients, has a significant impact on their mortality and might be involved in the incidence of CKD in them. Allo-SCT recipients who have developed early AKI should be observed with the utmost care, as such AKI could be a fatal adverse event.
Further investigation targeting AKI prior to stem-cell engraftment is anticipated globally in order to confirm its significance. Figure 3 . Cumulative incidence of CKD over 2-year period after the stem-cell infusion, stratified by early and late AKI. Cumulative incidence of CKD is shown, stratified by early and late AKI. An asterisk (*) indicates the significant difference between the AKI groups (P = 0.048).
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